Botulinum toxin type A for treating chronic low back pain: A double blinded randomized control study

Table 1 Demographic profile of the patients

Variables	Placebo	Botulinum toxin	P value
Age (mean ± SD)	39.5 ± 7.55	40.62 ± 9.13	0.67
Male:female	9:11	13:7
Mean duration of pain (months)	15.20	15.05	0.97
Body mass index (mean ± SD)	23.93 ± 4.23	23.94 ± 3.65	0.99

Table 2 Baseline serum values of biochemical parameters

Variables	Placebo (mean ± SD)	Botulinum toxin (mean ± SD)	P value
Serum calcium (mg/dL)	9.29 ± 0.36	9.29 ± 0.65	1.00
Serum alkaline phosphate (IU)	90.1 ± 37.5	81.19 ± 25.20	0.38
Serum phosphate (mg/dL)	3.36 ± 0.61	3.43 ± 0.39	0.66
Serum vitamin D (mg/dL)	8.95 ± 4.15	10.05 ± 3.69	0.38

Table 3 Outcome scoring in both groups

Variables	Placebo (mean ± SD)			Botulinum toxin (mean ± SD)
	Pre	Post	P value	Pre	Post	P value
VAS	6.7 ± 0.92	2.85 ± 1.08	< 0.001	6.25 ± 0.55	2.45 ± 0.99	< 0.001
ODI	34 ± 4.58	19 ± 4.29	0.001	33.5 ± 3.76	17 ± 3.72	0.007

VAS: Visual analog scale; ODI: Oswestry disability index.

Table 4 Change in the outcome scoring between the groups

Variables	Placebo (mean ± SD)	Botulinum toxin (mean ± SD)	P value
Mean change in VAS	3.85 ± 0.81	3.8 ± 0.89	0.427
Mean change in ODI	15 ± 1.50	16.5 ± 2.41	0.012

VAS: Visual analog scale; ODI: Oswestry disability index.